Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07074444 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Nov 30, 2026 → Feb 28, 2027
See other at-risk trials from First Affiliated Hospital of Guangxi Medical University

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Phase 4 → not applicable Show 6 more changesShow less
    • Primary completion pushed from Nov 30, 2026 to Feb 28, 2027
    • Study completion pushed from Dec 31, 2026 to Feb 28, 2027
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: 5 to 4
    • Site details revised at 1 of 2 sites
    • Collaborators: details revised at 1 of 2 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 10, 2025 to Jul 22, 2025
    • Site details revised at 2 of 2 sites
    v2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate and compare the efficacy and safety of three commonly used antiparasitic drugs-albendazole, tribendimidine, and praziquantel-for the treatment of clonorchiasis, a liver fluke infection acquired by consuming raw or undercooked freshwater fish. This study aims to answer the following primary questions: How effective is each drug in achieving parasitological cure, as measured by clearance of Clonorchis sinensis eggs in stool? What types and frequencies of adverse events are associated with each treatment? Participants in this randomized, open-label trial will: Be randomly assigned to receive one of the three study drugs according to a predefined dosing regimen. Provide stool samples before treatment and at follow-up to assess for Clonorchis sinensis eggs. Undergo a second round of the same treatment regimen and repeated stool examination if eggs are still detected after the first course. Attend follow-up visits, which include symptom assessment and blood tests (hematology and liver function). Report any side effects, discomfort, or adverse reactions experienced during or after treatment. The findings from this study will help inform optimal therapeutic strategies for clonorchiasis in outpatient clinical settings.
Trial Details
NCT Number NCT07074444
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Collaborators: People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
Conditions
(from sponsor)
Clonorchiasis
Related terms Clonorchiasis
Enrollment 318 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov